Cara Therapeutics | CARA - Stock


Cara Therapeutics reported $900K in Stock for its fiscal quarter ending in March of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Cara Therapeutics USD 900K 0 Mar/2025
Chugai Pharma JPY 276.85B 30.52B Dec/2025
Cipla INR 61.6B 5.18B Sep/2025
Clal Biotechnology ILS 4.44M 0 Mar/2021
CSL USD 6.47B 327M Jun/2025
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
J&J USD 14.58B 392M Mar/2026
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Pacira USD 150.37M 2.49M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
RedHill Biopharma USD 3.17M 482K Jun/2025
Supernus Pharmaceuticals USD 110.77M 1.71M Mar/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025